Panacea Life Sciences Holdings Inc · OTC:PLSH

Panacea Life Sciences — Exactus — Merger or Acquisition (May 2019)

59 slides from Panacea Life Sciences's merger presentation, May 13, 2019

  1. Slide 1: Prepared for: Exactus, Inc. Board of Directors

    May 1, 2019 | / Prepared for: Exactus, Inc. Board of Directors

  2. Slide 2: Disclaimer

    DISCLAIMER The information contained in this presentation (the “Presentation” is being provided by Scalar, LLC, (“Scalar”) to the Board of Directors of Exactus, Inc. (-Exactus") pursuant to an engagement letter dated March 4, 2019 between Scalar and Exactus. The information that follows in the Prese

  3. Slide 3: Contents

  4. Slide 4: Table of Contents

    TABLE OF — CONTENTS EXECUTIVE SUMMARY BACKGROUND TRANSACTION OVERVIEW VALUATION ANALYSIS APPENDIX 7 35

  5. Slide 5: Executive Summary

    Be cufive siywMiary > 9 -

  6. Slide 6: Scalar engaged to provide fairness opinion on the Transaction

    The Board of Directors of Exactus, Inc, (GTC:EXDI) (herein referred to as “Exactus," “EXOI” or the "Company") retained Scalar, LUC (herein referred to as “Scalar” “we", “our”, oF “us") as an independent, qualified financial advisor to provide an opinion ("Opinion") as to the fairness, from a financi

  7. Slide 7: Secondary Purchase Agreement and total consideration

    ‘Scalar has been informed that Exactus and the Members entered into a Purchase Agreement dated March 4, 2019 (the “Secondary Purchase Agreement’). Based on the information provided by the Company, we understand that the structure of the Secondary Purchase Agreement involves the assignment to Exactus

  8. Slide 8: Diligence

    DILIGENCE Scalar performed the following procedures, analyses, and inquiries as we deemed necessary and appropriate under the circumstances. Among other things, * Discussed the rationale, timeline, and process leading up to the execution of the Secondary Purchase Agreement and Subscription Agreement

  9. Slide 9: Background

    BACKGROUND

  10. Slide 10: Hemp & CBD Industry

    HEMP & CBD INDUSTRY ‘+ Industrial hemp isa type of cannabis plant containing ess than 0.396 THC (tetrahydrocannabinol). which is the psychoactive component of the cannabis plant. Industrial hemp is cultivated for the plant's seed, fiber, and extracts derived from the plant's flowers, + One potential

  11. Slide 11: Company Overview

    COMPANY OVERVIEW + Exactus One World — Owns a 200 acre leasehold interest in Oregon comprising approximately 100 acres in the Rogue Valley and approximately 100 acres in the Ilias Valley. EOW is planting an exclusive genetic variant of hemp crop that Is expected to yield fifteen to eighteen percent

  12. Slide 12: Transaction Overview

  13. Slide 13: Transaction Overview

    TRANSACTION OVERVIEW Seller Percentage Sought gM Purchase Agreement actus, In Cees2Med, Lic ‘Subserintion Agreement - 30 Percentage Unt rset In ‘ractus One World LE 200% Purchase Agreement - 20:1 Percentage Units Exact, Ine. Shes Tomas Melovale& Acs Popejoy 20.1% 50.1% Purchase Consideration 12,600,

  14. Slide 14: Transaction Overview: Rights Purchase Agreement

    TRANSACTION OVERVIEW Rights Purchase Agreement oxor/z0n8 #2600000" 00 | #2600000 rot #2600000 | #2600.000 1. Payment of ExOI Convertible Preferred Stock with face value of $10 milan, convertible inte common ‘shares a a price of $4.00 with an elective date of March 1, 2019, 2.255 millon shares of €X0

  15. Slide 15: Transaction Overview: Subscription Agreement

    TRANSACTION OVERVIEW Subscription Agreement - 30 Percentage Units Date Amount Discount Facto Present Value 02/27/2019" $400,000 1.00 | '$400,000 03/01/2019 '$100,000 1.00 '$100,000 04/01/2019 500,000 1.00 5499000 (05/01/2019 +3500,000 1.00 +5498,000 (08/01/2019 $300,000, 098 $297,000 (09/01/2019 450

  16. Slide 16: Transaction Overview: Purchase Agreement 20.1 Percentage Units

    TRANSACTION OVERVIEW Purchase Agreement - 20.1 Percentage Units Date Amout Discount Factor® Present Value 03/04/2019 $300,000 1.00 | $300,000 03/04/2019 $1,050,000 4.00 $1,050,000 04/15/2019" $30,000 1.00 $30,000 (04/20/2019 700,000 1.00 $698,000 06/10/2019" $480,000, 099 $447,000 09/01/2019 $500,00

  17. Slide 17: Valuation Analysis

    — =a ON ANALYSIS f Yan NAS

  18. Slide 18: Valuation Analysis

    VALUATION ANALYSIS Fair Market Value of Exactus One Worl Enterprise Value Range li 75th Percentile Discounted Cash Flow Valuation - Revenue Multiple Terminal Value (Income) $74,080,000 585,350,000 100,140,000 Discounted Cash Flow Valuation - H-Mode! Terminal Value (Income) $59,210,000 $67,400,000 $7

  19. Slide 19: Valuation Analysis

    VALUATION ANALYSIS Fair Market Value of Exactus One World, LLC as of March 0. Enterprise Value Range 25th Percentile 75th Percentile Discounted Cash Flow Valuation - Revenue Multiple Terminal Value (Income) $74,080,000 585,350,000 100,140,000 Discounted Cash Flow Valuation - H-Mode! Terminal Value (

  20. Slide 20: Valuation Analysis

    VALUATION ANALYSIS a a eres oth WA 00% asm 1s tps (ot) om toon toa 1 vw Notes: Exactus management provided the Forecast to Scalar. Exactus management also stated that the {genetic variant of hemp is expected to yield 15% - 18% CBD per pound, which willbe sold at an expected price of $3.50 per percen

  21. Slide 21: Valuation Analysis

    VALUATION ANALYSIS Data Source Panxchange Kush Marketplace - 2017 Kush Marketplace - 2018 Kush Marketplace - 2019 (Forecast) ‘New Frontier Data - Futures Contracts, 2017 and 2018 New Frontier Data - Spot Pricing, 2017 and 2018 New Frontier Data - High CBD % Spot Pricing, 2017 and 2018 Median Mean He

  22. Slide 22: Valuation Analysis

    VALUATION ANALYSIS Hemp Biomass ($ per Ib per % of CBD)

  23. Slide 23: Valuation Analysis

    VALUATION ANALYSIS Notes: Exactus management did not provide a balance sheet as of the Valuation Date. Exactus management did not provide any historical or projected balance sheets In response to an email from Scalar dated April 15", 2019 asking if there were any assets or liabilities present on the

  24. Slide 24: Valuation Analysis

    VALUATION ANALYSIS Discounted Cash Flow Projections ending Dec 3 in USD 5000's 2018 2019 2020 2021 2022 2023} Total Revenues 2 $2557 $65,113 95208 $113,169 $142,931 Revenue Gronth Rate WA 100.0% 463% 16.7% 28.6% eerroa s2a916 ‘57932 $04.26 ‘90900 $127,288 cor $2566 ‘57832 ‘04.726 $9080 $127,188 ‘Tax

  25. Slide 25: Valuation Analysis

    VALUATION ANALYSIS Cost of Eau « eden Pens, eh. a Shin Se 75.0% Required Return forVentre-Backed Companies costofoent = md company Sorte Cott Bn 200% evelopment Stage Plummer ——-—Schetis.eta Sabimansta. Equity /Toraicap +07 ey esr 0 95% stucup 50-70% 070% 50-10% wace 7 fe/v) 9a C4 aneate)*C1-E7VDT 4

  26. Slide 26: Valuation Analysis

    VALUATION ANALYSIS 2023 Revenue $142,931 25th Percentile Multiple - Public Comps 35x Estimated Exit Value $493,193 Discount Rate 74.1% PV of Terminal Value $33,859 Weighted Average Cost of Capital 74.1% ‘Summed Present Valves of Discrete Period Cash Flows $52,278 Present Value of Terminal Value ~ Re

  27. Slide 27: Valuation Analysis

    VALUATION ANALYSIS ‘minal Value: H-Model “Terminal Year Cash Flows rem 988,132 wace TAA% Years of High Growth 50 Halt-ite " 25 Long-Term Growth Rate « 3.0% High Growth Rate 6 249% 2023 H-Model Value Ferra Ferns 01/ O) $195,398 + 2025 Discount Factor 0.08 PV of Terminal Value $15,105 Weighted Average

  28. Slide 28: Valuation Analysis

    VALUATION ANALYSIS rminal Value “Summed Present Values of Discrete Period Cash Flows $52,278 Market Value of Invested Capital (Rounded) $64,800 Notes: The perpetuity growth method assumes a long-term growth rate that will be used to capture the value of the company Into perpetuity. The rate is appli

  29. Slide 29: Valuation Analysis: Public Companies

    VALUATION ANALYSIS Public Companies

  30. Slide 30: Valuation Analysis

    VALUATION ANALYSIS

  31. Slide 31: Valuation Analysis

    VALUATION ANALYSIS

  32. Slide 32: Valuation Analysis

    VALUATION ANALYSIS

  33. Slide 33: Valuation Analysis

    VALUATION ANALYSIS LESEESESSESESSCESESTE Enns

  34. Slide 34: Valuation Analysis

    VALUATION ANALYSIS

  35. Slide 35: Appendix

  36. Slide 36: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS ‘canopy Growth Corporation iray. ne. Canopy Growth Corporation together wih issubsaresengses i growing poststlon, and sl of mes! cannabis a Canadas prods nce ried toners, els and concetates, “Toe company wos Frey now a Twees Marca ne and changed is ramet Canoy G

  37. Slide 37: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS ‘Aurora Cannabis ne. ‘Curaleat Holdings ne. arora Cannabs ie produces and estrous mesetcnnsbs procs erty integrate an horzontaly Serie scons various vgments ofthe ‘cannabis value chain, rom fcityengnerng and design to cannabis breeding genetics research, product

  38. Slide 38: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS arvest Heath & Recreation Inc. ares Heo & Recreation ne. eulats, manufactures, na ret canna in the United States, The company Is headmateredn Vancouer Conse ‘Tralleve Cannabis Corp. Maries ie isrbutes ts produto Trev branded stores (pense) n Fleas wll a tet ta p

  39. Slide 39: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS brane Cptal Hots, ne owns and operates cesed canna culation, processing dnd sensay frites nthe Unites Sttes. sof Ape 16,2019, 8 ‘atin Cai Helos, ne partes 21 aiensaiesin 11 states The company tx basen New Yor, New York 174 Corp. a blophamaceucal and wellness com

  40. Slide 40: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS Pharmacie, tough te sobscary, Pharmacia Colombia Holdings SA'S, culvates process, produces nd supplies medal grade ca sna relted pracuts in Clon an iteration It provides annals etrahyroransbin acute cannabe ol erate or na sharmacies, mea cis, and cote companies

  41. Slide 41: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS Westleat te. Wee! ine engages in the euthaton. extraction, dutbutan and tal of cannabis and conabi rele products The compsnyihesdqurtere a Calan cana, ‘The Flone Corporation Flower One Holdings tne ‘The Flow Corporation cutter and produces medicinal cannabis in

  42. Slide 42: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS ‘maven Group, Ine. ‘Aleafia Heath tne uaran Group, ne. trough ts subssres, operates a a spectaed conabis management company rimaiy nthe Unted Sates and Canada, The company offers ts arnes tary cannabis cutvation, processing and eta solitons, nln eansure supp, el

  43. Slide 43: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS Planet 13 Holdings Ine ‘One World Pharma, tne. {eC iterations Cannabis Corp Pane 13 Holdings in. anna compeny uve, produces, and dtbues media ang recratonlcannabisin Neves, he Untes State, Tas operates <dspensaves that prove recreational annabs, cannabis etacs,

  44. Slide 44: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS ‘Chemesis Internationa Ie “48North cannabis Corp ‘Cannara Biotech Ine hemes tnereationa! In. tooth Colombia. proves various pena teed in Vancouver, Canad reads proauctsin Calf, Peco Ro, ad enol extraction, nd C2 extraction. The company «aNorth Cannabis Corp oper

  45. Slide 45: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS arrest One Cannabis ne, develops and prove sydd welness products o consumers and tet in eguaies malas wovdwie. 1 operates trouDh thee segments Cuttin, Mase! and Nurses, nd Caumer, The company culate and dtetes cannabis and process, manuacars, nd crates ‘cannabis

  46. Slide 46: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS ‘eteaBio-Pharm ine 21 Investments tne Tetra Bio-Pharme re. 9 degen stage coma. engses ne ceveopment of be pharmaceuticals and natura Relhoroduct ontaiing cannabis ond ther medicinal pan ase element Cand ts ead reduc PPPOO!, ried cannabis presen seu for acvanced

  47. Slide 47: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS General Connbis Corp prvies product and services to the equsedconadbisndusry ad ron-cannais customer Inthe United State. The compeny operates nour ngments Securty an aa ‘General Cannabis Corp ng customer-speciie apparel and acessories. toler seciay T-shirt and g

  48. Slide 48: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS tron (CHD) Reta Sale Manan Techeloges: and Arcture. The EMO segment de a eit canbi and herb rome in the mare, 9 wel ase ioe, and alin sae of electronic cigs CBD products and echrologes segment operates 420clod, » acl lator fr cig, Ine insted planing ana rowing s

  49. Slide 49: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS ‘GrowGeneration Corp. ‘Terra Teeh Corp. i byroponic equipment toting pan nates, on various rats elstedmavhets Aso cee 1 ren Reva, and cen Washington The GronGeneration Coro trough ls subsites operates ret hyeroponi ores. les ter products. The compny serves hame

  50. Slide 50: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS ‘choom Holdings In, Choom Klengs ne. hough ts subir. MealCan Mest Sldion Lt. enaaes in cutvating ad seting canna for mel prpess and related roots ‘ie company was formery known a Sandor Graphite Crporaton and changed is amet Choom Hoang rn November 2017, Chaom Ho

  51. Slide 51: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS James Wagner Cutvation Corporation Biome Grow ie. Newaeige Global Ventures, in. James € wagne ultration Corporation though ts subsiiny James Wagner Cultwaton Ld. engages in the ulthation a 1oterscamatone, rockstar hus, ia laughing. and chemcane products, The com

  52. Slide 52: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS (Md Holdings, tne. Medicine Man Technologies ne Freedom Leaf Ine olds ne, troughs subsisanes, operates medical moran businesses In Nevado ors inasrctre, contraction, cinaten management proicton manager, cation consung and eperaing services to clhatlon an product

  53. Slide 53: Guideline Public Company Descriptions

    GUIDELINE PUBLIC COMPANY DESCRIPTIONS CannaPharmaRX ne ne doe ot have slonfcant operations tend to engoe In caulans Ojai ventures wth compony composi Inthe cannabis revi, Awa persed a a phrmaceatal aman, The company i bare avn, Calor GTEC Holdings Lt {6B Sciences, Ine ‘Seances, Inc hasan apreemet wi

  54. Slide 54: Scalar

    8 Scalar Zak Nugent Matt Fix, CFA CEO, S€nior Associate zak.nugent@sc¢alar.io mfix@scalar.io

  55. Slide 55: Fairness opinion letter, May 3, 2019

    ©Scalar May 3, 2019 Jonathan Gilbert Chairman of the Board Exactus, Ine, (OTCENDI) 80 NE 4 Avenue Del Ray Beach, FI. 33483 Dear Mr Jonathan Gilbert, As per our engagement lettce dated March 4, 2019 (he “Engagement Letter"), the Board of Directors of :sactus, Ine. (OTCEXDI) (herein refered to as "Exa

  56. Slide 56: Transaction Consideration and Scalar's procedures

    ©Scalar “The Company, as party to each of the prior transactions, incurs a Rights Purchase Consideration of an «estimated $2.6 million, a Subscription Consideration of $2.7 million, and a Secondary Purchase Consideration ‘of an estimated $3.0 million, for a tora Transaction Consideration of $8.3 mil

  57. Slide 57: Opinion assumptions and reliance

    ©Scalar information has been reasonably prepared based on assumptions reflecting the best currently available estimates and judgments of the management of Exactus as to the expected furure results of operations and financial condition of EOW and its programs. We assume no responsibilty for and expre

  58. Slide 58: Opinion limitations and fees

    ©Scalar this Opinion or otherwise comment upon any events occurring after the date hereof, material information provided to us after the date hereof, or any change in fats or circumstances that occur after the date hercof, and do not have any obligation to update, revise or reaffirm this Opinion. We

  59. Slide 59: Fairness opinion conclusion

    O Scalar Based upon and subject to the foregoing, itis our opinion that the Transaction Consideration is fa from a financial point of view, to the Company as of March 4, 2019. Scalar, UC Scalar, LLC ate: May 3, 2019

Exactus — Merger or Acquisition (May 2019) on 6ix